Improving the Utility of In Vitro Test Methods for Intranasal Drug Delivery

In this article, Dr Clair Brooks, Applications Specialist, and Matthew Fenn, Head of Business Development, discuss the development and validation of the Alberta Idealised Nasal Inlet (AINI), exploring how it can be used to optimise intranasal drug delivery and provide a realistic assessment of pulmonary deposition risk.

This article is taken from from Inhalation Magazine April 2024.

Download PDF

Improving the Utility of In Vitro Test Methods for Intranasal Drug Delivery

Training & Support

Find out more about the broad range of training opportunities and comprehensive support we offer customers

Training

We offer a range of training courses, presentations and seminars covering a wide range of topics Find out more

Servicing

A comprehensive range of both in-house and on-site product servicing options are available Find out more

Support

Our team of experienced technicians and engineers are on hand to help and advise Find out more

Downloads

Access the latest product brochures, whitepapers and other useful content

Find out more

First Name *

Last Name *

Email Address *

Organisation Name *

Message *

Please review our privacy policy so you understand how we collect and use your personal data.

Captcha

Improving the Utility of In Vitro Test Methods for Intranasal Drug Delivery

Establishing an Optimal Test Set-up for Delivered Dose Uniformity Testing for Nasal Drug Products

Improving Performance in Inhaled Therapeutics

Reducing Variability in the Inhaler Testing Environment

Better In Vivo Prediction from OINDP Testing: A Goal Worth Pursuing?

OINDPnews Q&A With Copley’s Clair Brooks on In Vitro Testing for LGWP MDI Reformulation

Matching DUSA and Impactor Rise-Time Profiles With A Volume and Resistance Compensator